INTRODUCTION
There are approximately 33 million people infected with the human immunodeficiency virus (HIV) worldwide 1 . Many believe that the only way to effectively prevent the ongoing spread of HIV is to develop a protective vaccine. Consequently, it has become increasingly important to understand how HIV interacts with its host and under what conditions the immune system is able to effectively control viral replication and limit disease progression.
Crucial to understanding immune control over viral replication in humans is the study of those rare individuals who remain healthy in the absence of antiretroviral therapy. Initial studies focused on individuals who maintained normal CD4+ T-cell counts for over 10 years (long-term non-progressors, or LTNP) 2 ; such individuals comprise between 5 and 15% of the chronically infected population. Plasma HIV RNA levels were often low in these individuals, but there were exceptions. Since many factors may prevent disease progression, we and others have increasingly defined non-progressors based on plasma HIV RNA levels. Two distinct groups have been identified: those who maintain undetectable plasma HIV RNA levels, "elite controllers," and those who have persistently detectable but low plasma HIV RNA levels, "viremic controllers." Elite controllers represent less than 1% of the HIV infected population 2 .
Cytotoxic T-cells (CTL) are important in the initial decline of peak viremia during acute HIV infection and the determination of viral set point during chronic infection, a measure that often predicts progression rates to AIDS [3] [4] [5] . Despite a strong initial response from HIV-specific CTL during primary infection, these cells are unable to completely clear the virus. As chronic infection ensues, HIV-specific CTL begin to lose function [6] [7] [8] . However, several studies have shown that individuals with better control over viral replication retain circulating HIV-specific CTL with higher capacities for cytokine production [9] [10] [11] [12] [13] , perforin expression 14 , and proliferation
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Several host genetic factors have been associated with viral control and protection against disease progression. Most frequently cited is the enrichment of certain class I HLA alleles, in particular HLA-B27 and B57, among HIV controllers [17] [18] [19] . Much less is known about the potential role of class II HLA molecules in HIV infection; however, a few reports have suggested an association of HLA-DR13 and /or DQ6 with the LTNP phenotype [20] [21] [22] .
Cell-mediated immune responses are typically studied in peripheral blood due to the ease of obtaining samples from this compartment. However, much of the virus, and presumably much of the host response, resides in lymphoid and mucosal tissues. HIV replicates to substantial levels in the gut 23, 24 , where a large proportion of the body's lymphocytes reside 25 , particularly activated memory CD4+ T-cells expressing CXCR4 and CCR5 26, 27 . These cells are highly susceptible to HIV infection and replication. Consequently, CD4+ T-cells in this compartment are depleted [28] [29] [30] and there is rapid emergence of mucosal CTL 27, 31 . Due to the differing microenvironments in peripheral blood and gut 32 , it is important to understand the differences in immune pressures imposed on HIV in these compartments. To date, very few studies have addressed the role of mucosal T-cell function in HIV infection, and there have been no comprehensive studies of mucosal T-cell function in a large, well defined group of HIV controllers.
To better understand how immune responses in the gastrointestinal tract relate to viral replication and disease progression, we analyzed HIV-specific T-cell function in paired peripheral blood and rectal biopsy samples from a well-characterized cohort of elite and viremic
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From controllers and compared them to non-controllers and patients on highly active antiretroviral therapy (HAART). While these correlative studies cannot definitively establish a causal role for mucosal CD8+ T-cells in protection from disease progression, our results do reveal that strong, polyfunctional CD8+ T-cell responses in gut mucosa are associated with the ability of some individuals to control viral replication and delay disease progression in the absence of antiretroviral therapy. Accordingly, mucosal T-cell responses may be one of several critical immunological, virological and genetic factors that contribute to the "HIV controller" phenotype.
MATERIALS AND METHODS
Subjects and Tissue Collection. Most subjects were enrolled through an ongoing study of chronic HIV infection, based at San Francisco General Hospital. Some subjects were recruited through the Center for AIDS Research, Education and Services (CARES) clinic in Sacramento, CA. Five unique groups were recruited. Elite controllers were defined as antiretroviral untreated individuals with plasma HIV RNA below <75 copies/mL on at least three occasions. Viremic controllers were defined as antiretroviral untreated individuals with plasma HIV RNA between 75 and 2,000 copies/mL on at least three occasions. Non-controllers had viral loads consistently above 10,000 copies/mL in the absence of antiretroviral therapy, and the HAART-suppressed group included individuals with plasma viremia artificially suppressed below the limit of detection (<75 copies/mL) by highly active antiretroviral therapy (HAART).
HIV uninfected controls were also included. Written informed consent for phlebotomy and flexible sigmoidoscopy was obtained from all individuals in accordance the Declaration of Helsinki, and with study protocols approved by the Institutional Review Board, University of 
Statistical Analysis.
To analyze response data, we first determined whether antigenspecific responses differed significantly from the negative control using a previously described formula that assumes a Poisson distributions for both conditions and takes into account the actual numbers of gated events rather than the percentages within the gates 37 . Net antigen-specific responses were then calculated by subtracting the negative control values from antigen-specific responses. This step was important, particularly for analyzing mucosal cells, since mucosal lymphocyte yield is generally small and these partially activated cells have been shown to produce low levels of cytokines in the absence of antigen-specific stimulation 32, 36 .
Comparisons between two groups (tissues or patient groups) were done using a two-tailed
Mann-Whitney test in GraphPad Prism software (version 5, GraphPad Software, San Diego, CA).
Correlations between variables were done utilizing the Spearman correlation and linear regression was used to graph a best-fit line to the data (GraphPad Prism). Statistical analysis of Boolean-gated data (polyfunctional responses) were performed in SPICE software using the Wilcoxon-Rank test to compare individual polyfunctional response categories at a significance level of P<0.01 and a permutation test, based on chi-square statistics, to compare pie charts.
RESULTS

Baseline characteristics
This study included 52 HIV-infected subjects and 8 uninfected, healthy controls. Each of the 52 HIV-infected subjects was assigned to one of four categories based on viral load and treatment status: elite controllers (no antiretroviral therapy, plasma HIV RNA <75 copies/ml, n=17), viremic controllers (no antiretroviral therapy, plasma HIV RNA 75 to 2000 copies/mL, n=11), non-controllers (no antiretroviral therapy, plasma HIV RNA >10,000 copies/mL, n=14), and HAART-suppressed (on treatment, plasma HIV RNA <75 copies/mL, n=10). The median blood CD4+ T-cell counts at the time of the analysis were 765, 475, 510, 488, and 692 for the elite controllers, viremic controllers, non-controllers, HAART suppressed subjects, and HIV uninfected controls respectively (Table 1) . 
Mucosal Gag-specific responses are strongest in controllers
Multicolor flow cytometry was used to assess HIV Gag-specific T-cell responses in blood and rectal mucosa. A representative gating strategy for rectal mononuclear cells is shown in Figure 2a . Doublet and dead cell discrimination were used to reduce background noise. For CD8+ T-cells, positive responses for each individual function (CD107a, IFNγ, IL-2, MIP-1β, and TNFα) were selected. Conventional bivariate plots were also created to confirm the placement of individual gates. A representative subject from the elite controller group is shown in Figure   2b . Boolean gates were created from the five individual gates to produce 31 distinct responding populations, encompassing all possible combinations of these five functions.
The total HIV-specific CD8+ T-cell response was determined as the percentage of cells capable of responding in any way to Gag stimulation after the subtraction of background ( Figure   3a ). Both elite and viremic controllers had significantly stronger mucosal CD8+ T-cell responses than either non-controllers or HAART-suppressed subjects (medians: 6.9% elite controllers and 6.4% viremic controllers vs. 4.1% non-controllers and 1.4% HAART; P<0.05 for elite controllers vs. non-controllers, P<0.01 for other pairwise comparisons). The total Gag-specific CD8+ T-cell responses were more similar in peripheral blood (3.0%, 4.3%, and 2.9% for elite controllers, viremic controllers and non-controllers, respectively), but responses in all three offtreatment groups were stronger than responses in the HAART group (1.3%; P<0.05 compared to viremic controllers, P<0.01 compared to elite controllers and non-controllers).
We also compared response magnitudes in blood versus mucosa for each patient group.
Although we did not quantify individual memory/effector T-cell subsets in this study, it is well known that peripheral blood includes many naïve T-cells, while mucosal T-cells are primarily effector memory cells 40 . We would therefore expect higher magnitude responses in rectal mucosa compared to blood. Indeed, we found mucosal CD8+ T-cell responses to be consistently higher than responses in blood for most patients; however, this difference was significant only in the case of elite controllers (P=0.034) (Figure 3 ).
Mucosal IFNγ, MIP-1β and TNFα responses in controllers are particularly strong
HIV Gag-specific CD8+ T-cell responses were further broken down into individual functions (IFNγ, IL-2, MIP-1β, TNFα and CD107a,) (Figure 3b-e) . Elite and viremic controllers had significantly stronger mucosal Gag-specific CD8+ T-cell responses than non-controllers for IFNγ, MIP-1β, and TNFα (P<0.05, Figures 3b, c, d , right panels). Again, the differences in PBMC were less robust, although elite and viremic controllers had higher responses than HAART suppressed patients (Figures 3b, c, d , left panels). IL-2 production by Gag-specific CD8+ T-cells was generally very low, and no differences were found between patient or tissue groups (data not shown). Degranulation (CD107a) responses were generally higher for the elite controller, viremic controller, and non-controller groups than for patients on HAART in either blood or mucosal tissue (P=0.0532 for elite controllers vs. HAART in blood, all others P<0.01; Figure 3e ).
Higher frequencies of polyfunctional CD8+ T-cells in rectal mucosa of controllers.
We next analyzed the complexity of the CD8+ T-cell response by looking at all five functional parameters in various combinations. To do this we employed Boolean gate analysis, which expanded the five response parameters into 31 individual functional categories. The pie charts in Figure 4a show the overall pattern of functionality of HIV Gag-specific CD8+ T-cells in rectal mucosa. Elite and viremic controllers were grouped together into a single controller category as they did not differ significantly from one another (data not shown). The pattern of Gag-specific CD8+ T-cell response categories, as revealed by pie charts, differed significantly between controllers and HAART-suppressed individuals in both blood (P=0.0034, data not shown) and rectal mucosa (P=0.0004). As we reported earlier 36, 37 , mucosal Gag-specific CD8+
T-cell responses from non-controllers were also significantly more complex than those from patients on HAART (P=0.0157).
When comparing controllers and non-controllers, there were significant differences between groups in the "polyfunctional" 3-and 4-function populations (purple and navy pie slices, Figure 4a ; bar graphs, Figure 4b ). However, permutation tests did not reveal an overall 
Polyfunctional CD8+ T-cells produce more MIP-1β on a per-cell basis.
Previous studies have demonstrated that antigen-specific T-cells that produce multiple cytokines/chemokines (i.e., polyfunctional cells) also produce greater amounts of these analytes on a per-cell basis than monofunctional cells 9, 37, 41 . We wished to determine whether polyfunctional mucosal CD8+ T-cells (defined as those capable of five, four, or three functions) from controllers produced larger quantities of cytokines or chemokines than those from noncontrollers. We chose to examine the median fluorescence intensity (MFI) of MIP-1β as a representative effector molecule since it was the one factor common to all five major functional categories. As seen previously 37 
Association of HLA class I genotype with CD8+ T-cell response magnitude and polyfunctionality.
High resolution HLA class I genotyping was performed on DNA from the patients in this study (Supplementary Table 1 ). As observed in previous studies 12, 13, 18 , HLA-B57 was highly enriched in both elite and viremic controllers (41% and 46% respectively) compared to the noncontroller group (0%) (Figure 5a) . A recent study of the larger UCSF Controller cohort from which the current subjects were drawn also found a higher prevalence of HLA-B13, 27, 58, and 81 in controllers compared to non-controllers 12 . As expected, these alleles were also more prevalent in the controllers we studied here (71% and 64% in elite and viremic controllers, respectively) as compared to non-controllers (29%) (Figure 5a ).
We examined the functionality of CD8+ T-cells from controllers and non-controllers with and without protective HLA class I alleles. Controllers with protective alleles had a greater median response magnitude in rectal mucosa compared to peripheral blood (7.4% vs. 3.0%, P<0.001; Figure 5b and data not shown). In all other groups, response magnitudes were similar in the two compartments. Controllers with protective alleles had more robust mucosal responses than non-controllers with (7.4% vs. 2.3%, P<0.05) or without (7.4% vs. 5.0%, P<0.01) protective
alleles. There was a trend towards higher responses in controllers with protective alleles compared to controllers lacking protective alleles (7.4% vs. 4.4%, P=0.09).
Similarly, in rectal mucosa, controllers with protective alleles displayed greater response complexity than either controllers (P=0.0455) or non-controllers (P=0.0362) lacking protective alleles ( Figure 5c ). Controllers with protective alleles had higher frequencies of mucosal Gagspecific 4-and 3-function cells than any of the other patient groups (P<0.01; Figure 5d ).
Individuals with protective HLA class I genotypes have increased levels of CD4+ T-cells in rectal mucosa.
We also assessed the relationship between class I genotype and CD4+ T-cell percentages in peripheral blood and rectal mucosa. Individuals with and without protective HLA class I genotypes had similar levels of CD4+ T-cells in blood (Figure 6a ). In rectal mucosa, noncontrollers lacking protective alleles had significantly lower CD4+ T-cell percentages compared to controllers with or without protective class I genotypes (medians 13.7% vs 30.1% and 33.9%
respectively; P<0.01). There was no difference between the elite and viremic controller groups 
Stronger mucosal CD8+ T-cell responses in individuals with HLA-DRB1*13 and/or DQB1*06
To determine whether certain MHC class II alleles were associated with controller status, we also performed HLA-DR/DQ typing (Figure 5a ; Supplementary Table 1). We found that HLA-DRB1*13 and DQB1*06 were enriched among HIV controllers (70% elite controllers and 45% viremic controllers vs. 8% non-controllers) (Figure 5a ). These two alleles were previously reported to be associated with slow HIV disease progression in several cohorts 20, 21, 42 . In addition, 53% of elite controllers and 45% of viremic controllers, but none of the non-controllers, had one or both of these class II alleles in addition to at least one protective class I allele. We then compared Gag-specific responses in individuals with and without these class II alleles ( Figure 7) . Individuals who possessed one or both of these class II alleles as well as one or more protective class I allele had significantly higher median Gag-specific CD8+ T-cell responses (7.7%) in rectal mucosa compared to those with only protective class I HLA alleles (2.9%, P<0.05) and those lacking any protective alleles (4.8%, P<0.01; Figure 7a ). There was also a trend towards individuals with both class I and II "protective" alleles having higher magnitude mucosal CD8+ T-cell responses than those with only HLA-DRB1*13 and/or DQB1*06 (4.3%).
The presence of certain class I and class II alleles also appeared to confer an advantage in terms of mucosal CD8+ T-cell response complexity (Figure 7b ). Individuals with both
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DISCUSSION
Numerous studies have supported a relationship between blood CD8+ T-cell responses and HIV control 9, 10, 14, 43 . Here, we have expanded on these studies by examining for the first time HIV-specific CD8+ T-cell responses in gastrointestinal mucosal tissues from a large, wellcharacterized cohort of HIV controllers. The gastrointestinal mucosa is the largest lymphoid organ in the body, a major site of HIV replication [23] [24] [25] , and houses a significant population of effector memory CD8+ T-cells. Many of these cells are HIV-specific 27, 31, 36, 40 , yet their frequency and effector functions have not been thoroughly assessed.
In the patients studied here, CD8+ T-cell responses in rectal mucosa were more strongly associated with controller status than peripheral blood responses. Not only did controllers have higher magnitude Gag-specific mucosal CD8+ T-cell responses than non-controllers and individuals on HAART, but these responses were of greater complexity: that is, controllers had higher frequencies of mucosal CD8+ T-cells capable of three or more simultaneous effector functions. It has become increasingly clear that T-cell "quality" rather than magnitude alone is important in defining an effective immune response to HIV. Several studies have demonstrated that the production of IFNγ alone is insufficient to define a protective immune response 11, [44] [45] [46] [47] .
The term "polyfunctionality" has come to describe the ability of cells to produce multiple 45 . In the mouse model of Leishmania major, mice were administered several vaccine formulations and subsequently challenged; mice that demonstrated the greatest protection were those that produced the highest frequencies of polyfunctional cells (IFNγ+TNFα+IL-2+) 41 . In previous studies, polyfunctional T-cells were shown to be enriched in the blood of certain HIV-positive LTNP, and the presence of cells capable of five simultaneous effector functions negatively correlated with viral load 10 . However, it is important to keep in mind that strong, polyfunctional T-cell responses may also be viewed as the product of a relatively intact immune system, and that HIV controllers may be shielded from profound immunological damage by mechanisms other than CD8+ T-cell activity. Our findings do not suggest that polyfunctional mucosal CD8+ T-cell responses are sufficient for immune control:
some controllers in our cohort did not exhibit unusually robust CD8+ T-cell responses, and some with relatively strong mucosal CD8+ T-cell responses were in fact non-controllers. Accordingly, there remains an urgent need to explore additional factors contributing to HIV non-progression.
We observed a consistent association between certain class I HLA alleles and the CD8+
T-cell response, suggesting that MHC class I-restricted responses can contribute to immune control of HIV infection. Previous studies have shown certain class I alleles to be overrepresented in cohorts of HIV controllers, particularly HLA-B27 and B57 [17] [18] [19] . CD8+ Tcells restricted by these alleles represent a large proportion of the total immune response in LTNP 48 . In a recent study of individuals from the UCSF controller cohort, we observed that subjects with protective HLA alleles (HLA-B13, 27, 57, 58, and 81) had higher frequencies of 12 . In this earlier study, we argued that HIV-specific T-cell responses likely contribute to immune control of HIV infection, but that other, "non-T-cell" mechanisms also play a role. The findings of the present study confirm and extend our earlier work, and reveal that the gastrointestinal mucosa is a site of robust and polyfunctional CD8+ T-cell responses in many HIV controllers. Nevertheless, it remains apparent that CD8+ T-cell responses alone cannot fully explain the phenomenon of HIV control.
HIV-specific IFNγ+IL-2+ CD8+ T-cells in peripheral blood compared to those without
The preservation of a strong CD4+ T-cell population appears to be beneficial to the maintenance of CD8+ T-cell responses, and our findings suggest that certain class II alleles may be associated with polyfunctional CD8+ T-cell responses. The question remains as to why specific class I and II HLA alleles are associated with long-term viral control. First, T-cell responses restricted by these alleles may be targeting functionally important regions within the viral genome. Several studies have shown an association between Gag-specific CTL responses and low viral loads [49] [50] [51] [52] [53] [54] . Targeting of multiple Gag epitopes is associated with HIV control, while responses directed towards Env epitopes fail to limit viral replication 50 . It has also been shown that HLA molecules associated with slower disease progression preferentially bind peptides from the p24 region of Gag 49, 52, 53 . Gag is highly conserved, and mutations occurring in Gag often come with a high fitness cost to the virus 51, 55 . In particular, HLA-B57 targets a region of p24 involved in assembly 49, 51 , and CTL escape mutations in this region result in a significant fitness cost to the virus 51 . In addition to polyfunctionality, CD8+ T-cells restricted by certain 
